Institute of Bioethics and History of Medicine, University of Zürich, Zurich, Switzerland.
University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Pediatr Blood Cancer. 2022 Sep;69(9):e29792. doi: 10.1002/pbc.29792. Epub 2022 Jun 2.
Diffuse intrinsic pontine glioma (DIPG) is a rare, but lethal pediatric brain tumor with a median survival of less than 1 year. Existing treatment may prolong life and control symptoms, but may cause toxicity and side effects. In order to improve child- and family-centered care, we aimed to better understand the treatment decision-making experiences of parents, as studies on this topic are currently lacking.
The data for this study came from 24 semistructured interviews with parents whose children were diagnosed with DIPG in two children's hospitals in Switzerland and died between 2000 and 2016. Analysis of the dataset was done using reflexive thematic analysis.
For most parents, the decision for or against treatment was relatively straightforward given the fatality of the tumor and the absence of treatment protocols. Most of them had no regrets about their decision for or against treatment. The most distressing factor for them was observing their child's gradual loss of independence and informing them about the inescapability of death. To counter this powerlessness, many parents opted for complementary or alternative medicine in order to "do something." Many parents reported psychological problems in the aftermath of their child's death and coping strategies between mothers and fathers often differed.
The challenges of DIPG are unique and explain why parental and shared decision-making is different in DIPG compared to other cancer diagnoses. Considering that treatment decisions shape parents' grief trajectory, clinicians should reassure parents by framing treatment decisions in terms of family's deeply held values and goals.
弥漫性内在脑桥胶质瘤(DIPG)是一种罕见但致命的儿童脑肿瘤,中位生存期不足 1 年。现有的治疗方法可能延长生命并控制症状,但可能会引起毒性和副作用。为了改善以儿童和家庭为中心的护理,我们旨在更好地了解父母的治疗决策经验,因为目前关于这一主题的研究还很缺乏。
本研究的数据来自于对 24 位父母的半结构化访谈,这些父母的孩子在瑞士的两家儿童医院被诊断为 DIPG,并于 2000 年至 2016 年期间死亡。使用反思性主题分析对数据集进行分析。
对于大多数父母来说,鉴于肿瘤的致命性和缺乏治疗方案,他们对治疗或不治疗的决定相对简单。他们中的大多数人对自己的治疗决定没有遗憾。对他们来说最痛苦的因素是观察到他们的孩子逐渐失去独立性,并告知他们死亡是不可避免的。为了应对这种无力感,许多父母选择了补充或替代医学,以便“做些什么”。许多父母在孩子去世后报告存在心理问题,母亲和父亲之间的应对策略经常不同。
DIPG 的挑战是独特的,这解释了为什么在 DIPG 中,父母和共同决策与其他癌症诊断不同。考虑到治疗决策塑造了父母的悲伤轨迹,临床医生应该通过将治疗决策框定为家庭的深层价值观和目标来安慰父母。